FG_white.png

Early cancer detection from liquid biopsy

Genopole_white.png
GENE_IO_white.png
cancer_campus_white.png
 
blue_light.png

Our Technology

Floating Genes is developing the NGS-based targeted sequencing technology “Enhance-seq” to detect rare mutations (patent submitted). Enhance-seq is highly sensitive to detect few molecules of rare circulating tumor DNA (ctDNA) in a strong background of non-mutated DNA with a very low sequencing depth.

Our Story

Founded in 2021 by Dipanwita Biswas and Gabriel Lerebours, Floating Genes is incubated in the Gene.IO program of Genopole. A proof of concept of the technology has been conducted in the Shaker program of Genopole.

Floating Genes aims at improving early cancer diagnosis with highly sensitive NGS-based technology. The company is developing in vitro diagnosis tests based on liquid biopsy.

diya_gab_square.jpeg